Wellington Partners’ investment strategy spans all stages of company development. From early stage to expansion stage to maturity, we fund companies based on their sector, technology, anticipated development timelines, and growth rates.

In Therapeutics, we mainly focus on the early stages of clinical development and on development activities that lead to a strong clinical proof of concept with the potential to trigger a liquidity event for shareholders. However, we are also willing to consider an investment based on a preclinical proof of concept for a highly innovative technology platform that allows for the generation of multiple high-value products.

In Diagnostics and Medical Technology, we prefer to invest in companies with product candidates already approaching regulatory approval, or even companies who have launched a first product. As a basis for an investment, it is essential that the technologies and product candidates have strong intellectual property protection and address significant market opportunities.